

- AE
- (a) an immunogenic peptide fragment of vascular endothelial growth factor; and
 - (b) a pharmaceutically acceptable carrier such that the composition is immunogenic for vascular endothelial growth factor when administered to a human or animal.

48. (New) The method of Claim 47, wherein the immunogenic peptide comprises SEQ ID NOS: 3-9.

49. (New) The method of Claim 47, wherein the pharmaceutically acceptable carrier comprises liposomes, colloidal gold, and carrier proteins.

REMARKS

The present invention is directed to immunogenic compositions comprising fibroblast growth factor and/or vascular endothelial growth factor, to methods for treating cancer or hyperproliferative disorders in humans or animals, and also to methods for treating humans or animals in need of an immune response to a growth factor.

Claims 4-49 are pending. No new matter has been added and support for the claims in found in the specification.

In light of the amendments Applicants are of the opinion that Claims 4-49 are now in condition for allowance. Such action is respectfully requested. If the Examiner believes any informalities remain in the application which may be corrected by Examiner's Amendment, or there are any other issues which can be resolved by telephone interview, a telephone call to the undersigned attorney at (404) 949-2400 is respectfully solicited.

Respectfully submitted,

JONES & ASKEW, LLP



By: Sima Singadia Kulkarni
Registration No. 43,732

24th Floor
3424 Peachtree Road, N.E.
Atlanta, Georgia 30326
(404) 949-2400
Our File: 05213-0075